Fundraising as a Service (FaaS): The “Fast-Track to Closing”

The 2026 Mandate: From Summit Pitch to Series A Close

Are you a HealthTech founder ready to transform anxiety into confidence and convert potential setbacks into stepping stones? Picture your sleepless nights finally ending as inXso’s Fundraising as a Service (FaaS) becomes your strategic ally.

As you approach the pivotal Series A milestone, understand that pitching at the MTI25 Summit on March 16 is just the start.

Institutional investors in 2026 do not write checks based on pitches alone; they perform rigorous ‘Deep Diligence’ on your Evidence Maturity. Fortunately, inXso FaaS is crafted to address these challenges. By providing tailored support and expert insights, we help ensure your evidence withstands scrutiny and instills confidence in investors.

Provided by inXso, this FaaS package is designed to help you navigate the high-stakes weeks following your showcase. Embrace a partnership model: you retain control of your strategy while leveraging our expert “Red Teaming” and diagnostic tools. This collaboration not only ensures your plan will withstand the world’s most rigorous investor scrutiny but also enriches our experts with unique insights from your innovative approaches and challenges. By working together, you contribute to refining our tools and methods, creating a sense of shared growth and mutual benefit.

In 2026, regulatory compliance shifts from a hurdle to a key value driver, directly protecting your venture’s valuation. MTI25 FaaS enables you to turn regulatory and technical evidence into a clear, trustworthy narrative for institutional investors. Recent data shows that early regulatory alignment has led to valuation increases of up to 20% in comparable biotech deals, demonstrating the tangible impact of compliance on financial outcomes.

For context, biotech companies that align early with regulatory standards have seen median pre-money valuations rise from €30 million to €36 million, highlighting the substantial financial upside that early compliance can bring to the table.

The Stepwise FaaS Journey: Post-Summit Acceleration

1. Launch: The EIC Showcase Track (16 March)

Begin your journey on the main stage. Pitch directly to a selected audience of international Series A/B investors. Capture initial market feedback immediately.
Note: This is a focused institutional investor track, separate from the global €300,000 Pitching Competition. EIC beneficiaries are welcome to apply to both. Seats are limited; first-come, first-served. Ensure your spot by applying early.

2. Feedback Diagnostic: The Investor Readiness Scorecard (IRSc)

Immediately following the summit, we map the investor feedback against our proprietary IRSc tool, a process that provides far more than a conventional checklist. The IRSc uniquely identifies nuanced gaps and growth opportunities in areas like team dynamics, product innovation, and market positioning. By converting detailed feedback into actionable insights, founders can focus on specific enhancements that standard checklists often overlook.
  • Activity: Self-assessment across 6 dimensions (Team, Product, Market Moat, Business Model, Financials, Validation).
  • Outcome: A diagnostic report identifying exactly which “‘Evidence Maturity’gaps (Regulatory, Clinical, or Financial) are standing between you and a signed term sheet.

3. Strategic Pivot: The inXso Funding Strategy Roadmap

Using the inXso Funding Strategy Template, you refine your roadmap to address the specific concerns raised by the summit investors. Label each component of your roadmap with due diligence terms investors understand and value, such as ‘clinical endpoints’ and ‘CAC/LTV ratio.’ This ensures your plan is aligned with investor expectations and is shaped by proven expertise, thereby building instant credibility.
  • Activity: Align your Funding Plan and R&D milestones to 2026 regulatory checkpoints (FDA/MDR), ensuring clear regulatory progress for investors.
  • Execution: High-intensity “Red Team” review sessions where inXso experts stress-test your refined narrative.

4. Technical Reinforcement: Specialised Workshop

We provide the technical substance needed to close your identified gaps:
  • Regulatory Fast-Track: Guided workshop on the 2026 FDA transitions, EUDAMED (the new EU device database all VCs now ask about), and EU HTAR mandates.
  • Goal: Make your investment narrative bulletproof, so you enter investor conversations with maximum confidence and impact.

5. Operational De-risking: Specialist Consultations

Access specialised consultations based on your diagnostic results:
  • IP & FTO: Strategic review of your competitive moat.
  • Nordic Testbeds: Planning for real-world validation.
  • Goal: Expert-led review of your ‘Path to Payment,’ and supporting economic evidence (BIM).

6. Sustainability: Finalised Strategy & Monitoring (Closing May 31)

We support your investor follow-on meetings, provide final specialist feedback, and track your success journey to amplify your story within the EIC community.

Value Proposition: The ROI of your €1,350 Investment

The full FaaS package value is €2,700. EIC beneficiaries pay only €1,350 (50% co-funded via the EIC ACCESS+ initiative).
  • Valuation Protection: Confirming your regulatory path during the post-pitch weeks can justify valuations up to 25% higher in final negotiations. To illustrate, an efficient alignment with regulatory standards on a 4 million euro raise could lead to an increase in valuation by 1 million euros. Invest 1,350 euros to protect 1,000,000 euros in value on a 4 million euro raise, providing an ROI of 740 times.
  • Expert Leverage: Access 15+ hours of specialist time—including investment and regulatory experts from inXso—to handle post-summit due diligence queries. The open market equivalent for such advisory services would typically cost around €8,000, underscoring the exceptional value offered with this package.
  • Diligence Speed: Fast-track your funding journey by significantly cutting down the ‘Valley of Death’ period between the pitch and deal closure. On average, founders reduce diligence time from 180 days to just 90 days. By resolving technical red flags in April and May, you ensure a swift, smooth, and predictable closing process.
  • The FemTech “Alpha”: One top-performing FemTech venture will receive the MTI25 Women’s Health Pioneer Award and a €5,000 Regulatory Strategy Grant
    • Selection Criteria: Evaluation is based on strategic growth demonstrated during the post-summit review sessions.
Implementation: 16 March – 31 May, 2026.
Sector Focus: Biotech, Health/Medical Care, Pharma.

Common Questions from EIC Founders (FAQ)

Eligibility · Who can participate?

All EIC-funded startups (Pathfinder, Transition, and Accelerator) and Seal of Excellence holders are eligible. All EIC startups of any TRL level may apply. However, selection for the Showcase Track prioritises ventures within the Biotechnology, MedTech, and Pharmaceutical sectors that demonstrate a clear “investor readiness” potential.

Time Commitment · What is the founder's workload?

Founders should expect to commit 15–20 high-quality hours in total, which includes the summit pitching, followed by approximately 2 hours per week for diagnostic analysis, strategic refinement, and expert review sessions throughout April and May. The schedule is designed to be high-impact but “founder-friendly,” focusing on strategic refinement rather than administrative busywork.

Expert Access · How are sessions scheduled?

Following the summit, you are matched with inXso experts based on the technical gaps identified by investors. Sessions are scheduled through our digital portal and are conducted virtually, allowing for flexibility and accessibility. We utilize reliable video conferencing platforms to ensure smooth communication. This format enables participants to engage effectively with our experts regardless of their geographical location, ensuring a seamless integration of feedback and guidance.

Deliverables · What do I walk away with?

By the end of the program, you will possess:
  1. Showcase Entry: A confirmed slot on the EIC Showcase Track at the MTI25 Summit.
  2. The IRSc Diagnostic Report: A professional audit of your venture’s readiness, suitable for both internal assessments and initial investor discussions.
  3. The Stress-Tested Funding Strategy: A vetted version of your roadmap ready for final due diligence with VCs, ensuring alignment with regulatory requirements.
  4. Specialist Feedback: Written summaries and action points from your expert review sessions. that can be integrated into future strategic planning.
  5. Certificate: A Certificate of completion for the Regulatory Workshop, which can be referenced in regulatory submissions to demonstrate preparedness.

FemTech Award · How is the winner chosen?

The MTI25 Women’s Health Pioneer Award is open to all startups within the FaaS package that focus on women’s health (FemTech). The “highest-ranked” venture is determined by an expert panel evaluation of the venture’s impact potential and strategic clarity. The award includes a €5,000 Regulatory Strategy Grant to support an underserved sector.
APPLY NOW
MTI25